Antibiotics to insulin
•Download as PPTX, PDF•
0 likes•260 views
Essential medicines such as insulin, antibiotics, and some cancer drugs will increase in price by 3.8% starting April 1st. This is the first time drug prices have been allowed to rise since the BJP took power nationally. Over 500 drug formulations will increase in line with the annual Wholesale Price Index increase. The price hikes could significantly impact patients as some of these essential drugs are already expensive.
Report
Share
Report
Share
Recommended
Govt allows pharma cos to hike prices of 509 essential drugs
The Indian government has allowed pharmaceutical companies to increase prices of 509 essential medicines by 3.84% effective April 1. These medicines include those used to treat ailments such as diabetes, hepatitis, cancer, and fungal infections. The price hike is linked to the annual wholesale price index inflation rate of 3.84% between 2013 and 2014. Prices of condoms and antibiotics like amoxicillin have also increased. The government regulates drug prices under the Drug Price Control Order to improve healthcare access.
Why did d-penicillamine disappear from the market?
This document summarizes a talk on the shortage of the drug penicillamine in India. It discusses that penicillamine disappeared from the market in mid-2016 due to lack of raw material supply from China. The official reason was that the raw material supplier was unavailable, but the actual reasons may have been that the drug came under price control and suppliers did not want to provide raw materials at a competitive price. It also discusses the roles of the Central Drugs Standard Control Organization and National Pharmaceutical Pricing Authority in regulating drug prices and availability in India. The real issue highlighted is India's increasing dependence on China for drug ingredients and the need to support domestic bulk drug manufacturing.
Draft pharmaceutical policy 2017 by Ajay Raidas
The document outlines the need for a new pharmaceutical policy in India. Key reasons include high dependence on imports for APIs and intermediates, quality issues in domestic manufacturing, lack of R&D and molecule discovery. The proposed new policy aims to make India self-reliant in drug manufacturing, ensure quality, promote R&D and address unethical marketing practices. Major initiatives include establishing bulk drug parks, mandatory quality control tests, prescribing trade margins, encouraging generic medicines and amending NPPA's powers.
Market Structure and Factors influencing demand and supply of Cipla Ltd.
Cipla is an Indian pharmaceutical company and one of the leading players globally. It was founded in 1935 and has since expanded worldwide. The Indian pharmaceutical industry is large, valued at $41 billion, and supplies 20% of global medicines by volume. The industry has an oligopolistic market structure dominated by a few major players like Cipla, Sun Pharma, and Lupin. Demand for pharmaceuticals is driven by increased health awareness, insurance, government schemes, and rising incomes. Supply is affected by regulations, R&D capabilities, and access to new technologies. Cipla faces challenges from price controls, supply chain issues, and pandemic-related demand fluctuations.
Wiekang Biotech Investor Presentation, June 2010
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
Indian Pharma policy (Draft) 2017
New Indian pharma policy and its impact on Pharmaceutical Industry, Benefits to people, Impact on Imports, employment, skill development, marketing practices and impact of policy in ease of doing business.
ATS Company Reports: Unichem lab
ATS Company Reports: Unichem lab
Access Company Reports here: http://www.adityatrading.in/Research-Reports.aspx
Pakistan Pharma Overview
The document provides an overview of the pharmaceutical industry globally and in Pakistan. It discusses that global pharmaceutical sales will grow 5-6% annually to over $735 billion by 2008. There will be a shift in growth from developed to emerging markets and from primary to specialty care drugs. In Pakistan, the pharmaceutical market was worth Rs. 62 billion in 2007-08 and is dominated by therapeutic areas like gastrointestinal, vitamins and cardiovascular drugs. It also outlines marketing strategies used in the pharmaceutical industry like direct promotion to physicians.
Recommended
Govt allows pharma cos to hike prices of 509 essential drugs
The Indian government has allowed pharmaceutical companies to increase prices of 509 essential medicines by 3.84% effective April 1. These medicines include those used to treat ailments such as diabetes, hepatitis, cancer, and fungal infections. The price hike is linked to the annual wholesale price index inflation rate of 3.84% between 2013 and 2014. Prices of condoms and antibiotics like amoxicillin have also increased. The government regulates drug prices under the Drug Price Control Order to improve healthcare access.
Why did d-penicillamine disappear from the market?
This document summarizes a talk on the shortage of the drug penicillamine in India. It discusses that penicillamine disappeared from the market in mid-2016 due to lack of raw material supply from China. The official reason was that the raw material supplier was unavailable, but the actual reasons may have been that the drug came under price control and suppliers did not want to provide raw materials at a competitive price. It also discusses the roles of the Central Drugs Standard Control Organization and National Pharmaceutical Pricing Authority in regulating drug prices and availability in India. The real issue highlighted is India's increasing dependence on China for drug ingredients and the need to support domestic bulk drug manufacturing.
Draft pharmaceutical policy 2017 by Ajay Raidas
The document outlines the need for a new pharmaceutical policy in India. Key reasons include high dependence on imports for APIs and intermediates, quality issues in domestic manufacturing, lack of R&D and molecule discovery. The proposed new policy aims to make India self-reliant in drug manufacturing, ensure quality, promote R&D and address unethical marketing practices. Major initiatives include establishing bulk drug parks, mandatory quality control tests, prescribing trade margins, encouraging generic medicines and amending NPPA's powers.
Market Structure and Factors influencing demand and supply of Cipla Ltd.
Cipla is an Indian pharmaceutical company and one of the leading players globally. It was founded in 1935 and has since expanded worldwide. The Indian pharmaceutical industry is large, valued at $41 billion, and supplies 20% of global medicines by volume. The industry has an oligopolistic market structure dominated by a few major players like Cipla, Sun Pharma, and Lupin. Demand for pharmaceuticals is driven by increased health awareness, insurance, government schemes, and rising incomes. Supply is affected by regulations, R&D capabilities, and access to new technologies. Cipla faces challenges from price controls, supply chain issues, and pandemic-related demand fluctuations.
Wiekang Biotech Investor Presentation, June 2010
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
Indian Pharma policy (Draft) 2017
New Indian pharma policy and its impact on Pharmaceutical Industry, Benefits to people, Impact on Imports, employment, skill development, marketing practices and impact of policy in ease of doing business.
ATS Company Reports: Unichem lab
ATS Company Reports: Unichem lab
Access Company Reports here: http://www.adityatrading.in/Research-Reports.aspx
Pakistan Pharma Overview
The document provides an overview of the pharmaceutical industry globally and in Pakistan. It discusses that global pharmaceutical sales will grow 5-6% annually to over $735 billion by 2008. There will be a shift in growth from developed to emerging markets and from primary to specialty care drugs. In Pakistan, the pharmaceutical market was worth Rs. 62 billion in 2007-08 and is dominated by therapeutic areas like gastrointestinal, vitamins and cardiovascular drugs. It also outlines marketing strategies used in the pharmaceutical industry like direct promotion to physicians.
Final Management Thesis
The document provides an overview of the Indian pharmaceutical industry. It discusses the history and development of the industry from its origins in the early 20th century to the present day. Key events included the 1970 Patent Act which reduced costs by allowing reverse engineering of drugs. This strengthened the position of local companies against multinational corporations. The industry is now a $5 billion industry growing at 8-9% annually. It produces both bulk drugs and formulations and has established facilities for various dosage forms. The industry is transitioning as product patents come into effect in 2005.
Generic prescribing akmccc
This document discusses the initiative to prescribe medicines using international non-proprietary names (INN) rather than brand names. It notes that generics are significantly less expensive than brand name drugs but equally effective. Prescribing generics minimizes risks of confusion and improves patient adherence. Studies show generic prescribing rates are low in Pakistan compared to other countries. The document advocates increasing generic prescribing to improve quality of care and reduce costs.
Abbott laboratories pakistan (pvt) limited
This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.
Good Medicine Regulatory Distribution Practices in Pakistan
This document outlines good regulatory distribution practices for pharmaceutical products in Pakistan. It discusses the objectives to ensure all federal and provincial legal and regulatory compliances. The scope covers the issuance of pharmaceutical products to distributors across Pakistan. Responsibilities include distribution departments ensuring valid drug sale licenses before issuing orders. It provides definitions and discusses standard procedures such as verifying license validity. A table outlines the different license forms required for distributors and pharmacies in each Pakistani province.
Aon Canada Health & Benefits Drug Pricing Bulletin
A 20 January 2018 joint statement by the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA), on behalf of participating federal, provincial, and territorial public drug plans, announced a new five-year initiative that will provide significant drug plan savings to the provinces related to generic drug coverage. Though the primary beneficiary of the savings will be participating public drug plans, the Canadian Life and Health Insurance Association (CLHIA) has confirmed in a public statement that, “these discounts will continue to apply to employer sponsored plans,” thus private drug plan sponsors are likely to see notable financial savings.
indian pharmaceutical industry
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Mining of DPCO 2013
The document discusses a study analyzing the Drug Price Control Order (DPCO) 2013 in India. It finds that DPCO 2013 fails to control prices for over 80% of the pharmaceutical market due to several loopholes and shortcomings. Key exceptions include fixed-dose drug combinations, annual price increases, and patented drugs. The National List of Essential Medicines used to determine price controls also has inconsistencies and excludes many important drugs. Analyzing market data, the study demonstrates how categories like respiratory drugs and analgesics have 90-94% of their market uncontrolled due to these issues. It recommends improvements to the essential medicines list and national pricing policies to close loopholes and better achieve the goal of making medicines affordable.
Prescription Medicines Costs in Context April 2021
This document discusses the costs of prescription medicines in the United States. It notes that while brand medicine prices have risen 1.7% in 2019, in line with inflation, many patients still struggle with costs. It also discusses that prescription medicines make up only 14% of total healthcare spending in the US. Finally, it summarizes efforts by PhRMA to make medicines more affordable and accessible for patients.
Pharma Sector of INDIA
a brief about the pharma sector of India..which company are working in the Indian market and what is their respective positions...
Prescription Medicines Costs in Context October 2020
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
30 1337 22282
The domestic formulations market in India is expected to grow at a CAGR of 13-15% over the next 5 years, reaching over $1 trillion by 2016-17. Drugs for chronic diseases like diabetes, cardiovascular issues, and obesity will be the major drivers of growth, fueled by changing lifestyles in urban areas. Within therapeutic categories, anti-diabetic, CVS, dermatology, and neuro/CNS drugs saw the fastest growth in 2011-12. The anti-infectives segment remains the largest but grew more slowly due to price competition. Overall growth will continue to be driven by new product launches and volume increases, while a new drug pricing policy may slightly reduce market size but not
Growth of pharmaceutical industry
Indian pharmaceutical history began in the Gupta period from 320-550 CE, with foundational Ayurvedic texts like Charak Samhita and Sushruta Samhita. Allopathic medication was introduced during British rule but production occurred abroad until 1901, when Acharya P C Ray started the first Indian pharmaceutical company, Bangal Chemical. During World War 2, many pharmaceutical companies started in India to meet the 70% domestic demand when foreign supplies fell. India is now a major global producer and exporter of pharmaceuticals, ranking 3rd by volume, 14th by value, and 4th in generics. Its pharmaceutical exports have grown significantly each year.
Agha Campaigns Sandra Kiapi
The document summarizes AGHA's advocacy campaigns in Uganda to promote access to essential medicines, including their "Stop-Stock-outs" campaign. It found frequent stock-outs of malaria and antibiotic drugs in rural health centers due to underfunding of the health sector. The campaign pressured the government and resulted in reports of shortages, commitments to purchase more drugs, and calls to increase health sector funding to 15% of the national budget.
Nl healthcare aug 29 - sep 4, 2015
The Indian healthcare sector is expected to reach $280 billion by 2020, with a CAGR of 16%. The workforce is projected to reach 7.4 million by 2022. Medical tourism is estimated to increase to $10.6 billion by 2019. India has set new Sustainable Development Goals for the next 15 years to reduce mortality rates. Apollo Hospitals plans to expand operations in Kolkata and Bangladesh over the next few years. BPL Medical Technologies acquired UK-based Penlon to expand into new markets. Syngene International plans to invest $100 million in a new manufacturing plant in Mangalore.
Pakistan Drug Pricing Policy
This document outlines Pakistan's drug pricing policy, including:
1) Classifying drugs as scheduled or non-scheduled based on factors like public health significance and market share.
2) Setting formulas for pricing scheduled drugs based on costs in countries like India and Bangladesh.
3) Fixing prices for new chemical entities (NCEs) at 30% less than originator brands, and reducing originator prices over time.
4) Allowing annual price increases linked to consumer price index for scheduled and non-scheduled drugs differently.
Prescription Medicines Costs in Context April 2022
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Drug regulatory agency of pakistan ---------
The document discusses the establishment of a national Pharmacovigillance center in Pakistan to monitor adverse drug reactions and ensure drug safety. It outlines that the center would collect voluntary reports from healthcare professionals and the public on suspected adverse reactions, lack of drug efficacy, and pharmaceutical defects. The center would work to establish standardized Pharmacovigillance processes in Pakistan and expand monitoring to areas like antibiotics resistance, medical devices, and traditional medicines.
Prescription Medicines Insulin Costs in Context June 2019
This document discusses the history and development of insulin treatment for diabetes patients. It notes that while modern insulin allows for better management of blood sugar levels and health outcomes compared to the past, the rising costs of insulin have increased out-of-pocket costs for patients. The complex system of drug pricing in the US involves list prices, rebates provided to insurers and PBMs by drug companies, and cost sharing based on list prices rather than post-rebate prices, contributing to the affordability challenges for those with diabetes. Several policy solutions are proposed to help reduce patient costs and ensure access to needed insulin treatments.
Prescription Medicines - Costs in Context - October 2018
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.
Prescription Medicines Costs in Context March 2022
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
Freebies for docs from pharma firms
The Indian government has banned pharmaceutical companies from providing freebies like paid vacations and tickets to doctors and their families starting January 1. This is an effort to curb unethical marketing practices and influence of gifts on prescription decisions. The new Uniform Code of Pharmaceutical Marketing Practices prohibits gifts, hospitality, and samples to doctors from drug companies. It will initially be voluntary but may become mandatory if not effectively implemented in 6 months.
A device to manufacture organs
A new device called BioP3 allows for the assembly of larger living tissue structures from smaller microtissue components, which could eventually enable the manufacture of whole organs like livers or kidneys. In contrast to 3D bioprinting which prints one cell at a time, BioP3 uses pre-assembled living building blocks containing functional shapes and thousands of cells. The device precisely picks up and places the living microtissues under fluid suction to assemble structures without damage. The researchers demonstrated stacking rings and honeycombs of living tissues that naturally fused into cohesive wholes of over a million cells.
More Related Content
What's hot
Final Management Thesis
The document provides an overview of the Indian pharmaceutical industry. It discusses the history and development of the industry from its origins in the early 20th century to the present day. Key events included the 1970 Patent Act which reduced costs by allowing reverse engineering of drugs. This strengthened the position of local companies against multinational corporations. The industry is now a $5 billion industry growing at 8-9% annually. It produces both bulk drugs and formulations and has established facilities for various dosage forms. The industry is transitioning as product patents come into effect in 2005.
Generic prescribing akmccc
This document discusses the initiative to prescribe medicines using international non-proprietary names (INN) rather than brand names. It notes that generics are significantly less expensive than brand name drugs but equally effective. Prescribing generics minimizes risks of confusion and improves patient adherence. Studies show generic prescribing rates are low in Pakistan compared to other countries. The document advocates increasing generic prescribing to improve quality of care and reduce costs.
Abbott laboratories pakistan (pvt) limited
This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.
Good Medicine Regulatory Distribution Practices in Pakistan
This document outlines good regulatory distribution practices for pharmaceutical products in Pakistan. It discusses the objectives to ensure all federal and provincial legal and regulatory compliances. The scope covers the issuance of pharmaceutical products to distributors across Pakistan. Responsibilities include distribution departments ensuring valid drug sale licenses before issuing orders. It provides definitions and discusses standard procedures such as verifying license validity. A table outlines the different license forms required for distributors and pharmacies in each Pakistani province.
Aon Canada Health & Benefits Drug Pricing Bulletin
A 20 January 2018 joint statement by the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA), on behalf of participating federal, provincial, and territorial public drug plans, announced a new five-year initiative that will provide significant drug plan savings to the provinces related to generic drug coverage. Though the primary beneficiary of the savings will be participating public drug plans, the Canadian Life and Health Insurance Association (CLHIA) has confirmed in a public statement that, “these discounts will continue to apply to employer sponsored plans,” thus private drug plan sponsors are likely to see notable financial savings.
indian pharmaceutical industry
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Mining of DPCO 2013
The document discusses a study analyzing the Drug Price Control Order (DPCO) 2013 in India. It finds that DPCO 2013 fails to control prices for over 80% of the pharmaceutical market due to several loopholes and shortcomings. Key exceptions include fixed-dose drug combinations, annual price increases, and patented drugs. The National List of Essential Medicines used to determine price controls also has inconsistencies and excludes many important drugs. Analyzing market data, the study demonstrates how categories like respiratory drugs and analgesics have 90-94% of their market uncontrolled due to these issues. It recommends improvements to the essential medicines list and national pricing policies to close loopholes and better achieve the goal of making medicines affordable.
Prescription Medicines Costs in Context April 2021
This document discusses the costs of prescription medicines in the United States. It notes that while brand medicine prices have risen 1.7% in 2019, in line with inflation, many patients still struggle with costs. It also discusses that prescription medicines make up only 14% of total healthcare spending in the US. Finally, it summarizes efforts by PhRMA to make medicines more affordable and accessible for patients.
Pharma Sector of INDIA
a brief about the pharma sector of India..which company are working in the Indian market and what is their respective positions...
Prescription Medicines Costs in Context October 2020
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
30 1337 22282
The domestic formulations market in India is expected to grow at a CAGR of 13-15% over the next 5 years, reaching over $1 trillion by 2016-17. Drugs for chronic diseases like diabetes, cardiovascular issues, and obesity will be the major drivers of growth, fueled by changing lifestyles in urban areas. Within therapeutic categories, anti-diabetic, CVS, dermatology, and neuro/CNS drugs saw the fastest growth in 2011-12. The anti-infectives segment remains the largest but grew more slowly due to price competition. Overall growth will continue to be driven by new product launches and volume increases, while a new drug pricing policy may slightly reduce market size but not
Growth of pharmaceutical industry
Indian pharmaceutical history began in the Gupta period from 320-550 CE, with foundational Ayurvedic texts like Charak Samhita and Sushruta Samhita. Allopathic medication was introduced during British rule but production occurred abroad until 1901, when Acharya P C Ray started the first Indian pharmaceutical company, Bangal Chemical. During World War 2, many pharmaceutical companies started in India to meet the 70% domestic demand when foreign supplies fell. India is now a major global producer and exporter of pharmaceuticals, ranking 3rd by volume, 14th by value, and 4th in generics. Its pharmaceutical exports have grown significantly each year.
Agha Campaigns Sandra Kiapi
The document summarizes AGHA's advocacy campaigns in Uganda to promote access to essential medicines, including their "Stop-Stock-outs" campaign. It found frequent stock-outs of malaria and antibiotic drugs in rural health centers due to underfunding of the health sector. The campaign pressured the government and resulted in reports of shortages, commitments to purchase more drugs, and calls to increase health sector funding to 15% of the national budget.
Nl healthcare aug 29 - sep 4, 2015
The Indian healthcare sector is expected to reach $280 billion by 2020, with a CAGR of 16%. The workforce is projected to reach 7.4 million by 2022. Medical tourism is estimated to increase to $10.6 billion by 2019. India has set new Sustainable Development Goals for the next 15 years to reduce mortality rates. Apollo Hospitals plans to expand operations in Kolkata and Bangladesh over the next few years. BPL Medical Technologies acquired UK-based Penlon to expand into new markets. Syngene International plans to invest $100 million in a new manufacturing plant in Mangalore.
Pakistan Drug Pricing Policy
This document outlines Pakistan's drug pricing policy, including:
1) Classifying drugs as scheduled or non-scheduled based on factors like public health significance and market share.
2) Setting formulas for pricing scheduled drugs based on costs in countries like India and Bangladesh.
3) Fixing prices for new chemical entities (NCEs) at 30% less than originator brands, and reducing originator prices over time.
4) Allowing annual price increases linked to consumer price index for scheduled and non-scheduled drugs differently.
Prescription Medicines Costs in Context April 2022
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Drug regulatory agency of pakistan ---------
The document discusses the establishment of a national Pharmacovigillance center in Pakistan to monitor adverse drug reactions and ensure drug safety. It outlines that the center would collect voluntary reports from healthcare professionals and the public on suspected adverse reactions, lack of drug efficacy, and pharmaceutical defects. The center would work to establish standardized Pharmacovigillance processes in Pakistan and expand monitoring to areas like antibiotics resistance, medical devices, and traditional medicines.
Prescription Medicines Insulin Costs in Context June 2019
This document discusses the history and development of insulin treatment for diabetes patients. It notes that while modern insulin allows for better management of blood sugar levels and health outcomes compared to the past, the rising costs of insulin have increased out-of-pocket costs for patients. The complex system of drug pricing in the US involves list prices, rebates provided to insurers and PBMs by drug companies, and cost sharing based on list prices rather than post-rebate prices, contributing to the affordability challenges for those with diabetes. Several policy solutions are proposed to help reduce patient costs and ensure access to needed insulin treatments.
Prescription Medicines - Costs in Context - October 2018
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.
Prescription Medicines Costs in Context March 2022
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
What's hot (20)
Good Medicine Regulatory Distribution Practices in Pakistan
Good Medicine Regulatory Distribution Practices in Pakistan
Aon Canada Health & Benefits Drug Pricing Bulletin
Aon Canada Health & Benefits Drug Pricing Bulletin
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022
Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
Viewers also liked
Freebies for docs from pharma firms
The Indian government has banned pharmaceutical companies from providing freebies like paid vacations and tickets to doctors and their families starting January 1. This is an effort to curb unethical marketing practices and influence of gifts on prescription decisions. The new Uniform Code of Pharmaceutical Marketing Practices prohibits gifts, hospitality, and samples to doctors from drug companies. It will initially be voluntary but may become mandatory if not effectively implemented in 6 months.
A device to manufacture organs
A new device called BioP3 allows for the assembly of larger living tissue structures from smaller microtissue components, which could eventually enable the manufacture of whole organs like livers or kidneys. In contrast to 3D bioprinting which prints one cell at a time, BioP3 uses pre-assembled living building blocks containing functional shapes and thousands of cells. The device precisely picks up and places the living microtissues under fluid suction to assemble structures without damage. The researchers demonstrated stacking rings and honeycombs of living tissues that naturally fused into cohesive wholes of over a million cells.
54 kids die in 12 days at odisha
Fifty-four babies have died over the past 12 days at a government-run hospital in Odisha, putting the state government under scrutiny. Experts attribute the deaths to an overwhelming number of critical cases being referred to the hospital, which exceeds its capacity of 416 beds and limited intensive care facilities. Officials are investigating the matter while the opposition parties have criticized the hospital for not conducting postmortem examinations and demanded improvements to critical care in other parts of the state to reduce patient loads.
Created a bionic heart that does not beat
Australian researchers have developed the world's first bionic heart that pumps blood without a pulse. The device, called BiVACOR, was successfully implanted into a sheep. It uses magnetic levitation instead of sacs to pump blood, avoiding wear and tear that plagues traditional artificial hearts. The bionic heart could last up to 10 years, significantly longer than previous designs. Researchers hope to begin human trials within 3-5 years if additional testing and funding are secured.
Global shortage of injectables
Cadila Healthcare has emerged as the frontrunner to acquire the generic sterile injectables business of Claris Lifesciences for approximately $450-500 million. The deal underscores the increased interest in generic injectables due to a global shortage. Claris' focus on critical illness treatments and wide delivery capabilities make it an attractive target. The deal will help Cadila expand its presence in the growing injectables market, especially the US market. A formal announcement of the deal is expected in early next month.
A small us town scarred by a trusted doctor
Nearly 300 patients in Munster, Indiana have sued a prominent local cardiologist, Dr. Arvind Gandhi, and his partners, claiming they performed unnecessary medical procedures. An investigation was launched after patients grew suspicious of the high number of procedures Dr. Gandhi recommended. Some doctors had previously raised concerns about Dr. Gandhi's practice but were ignored because he brought in significant revenue for the hospital. Dr. Gandhi has since retired and denies any wrongdoing.
Final draft of ambulance code
The document summarizes key aspects of India's new ambulance code, which aims to regulate ambulances for the first time. The final draft code allows for two-wheeler ambulances to quickly transport patients, requires emergency exits and unfitted medical equipment, and will be mandatory. It has been adapted for Indian conditions from European standards. The code establishes four categories that ambulances can register under depending on their facilities and medical support level. It also aims to improve ambulance safety and compliance over time.
From 29 to 1.2k, dengue toll swings wildly
Two sets of data from municipal corporations in Delhi show vastly different dengue death toll figures over the last five years. One set shows 29 total deaths, citing data compiled specifically about dengue. However, another set shows a total of 1,221 deaths, citing data from death registrations compiled by the civic bodies. The large discrepancy between the two figures raises questions about which one accurately reflects the actual number of deaths caused by dengue in Delhi.
Viewers also liked (8)
Similar to Antibiotics to insulin
Drug exports to see $1.2bn hit on eu ban
The European Commission recently banned over 700 generic drugs due to alleged manipulation of clinical trials by an Indian company, GVK Biosciences. This ban will negatively impact Indian pharmaceutical exports to Europe, estimated at $1-1.2 billion annually. Europe accounts for $3 billion of India's total $15.4 billion pharmaceutical exports. Both Pharmexcil and the Indian government view the EU's decision as unjustified and lacking scientific basis.
Prices of essential drugs to be cut by 3% from april
The prices of essential drugs in India are expected to be reduced by approximately 3% starting in April. This would be the first across-the-board price reduction of essential drugs since 2013, in line with the annual wholesale price index decline of 2.75% from January to December. While most drug companies agree with the price change, some in the industry are opposed to the planned reduction.
Evolution of the healthcare industry in India and the potential impact of the...
2014 looks to be a positive but challenging year for the Indian health care sector; one in which many historic business models and operating processes will no longer suffice amid rising demand, continued cost pressures, lack of or inadequate care facilities, and rapidly evolving market conditions. India, likely will be dominated by the “Modi-care” –Health assurance for all.
Health care industry praroop jain
The health care industry in India is large and growing rapidly, expected to reach $158 billion by 2017. It makes up over 10% of GDP in developed countries. The industry is divided into hospitals, medicines/pharmacy, and medical supplies. Private sector participation has increased and now accounts for 66-81% of health care delivery. The government is also taking initiatives to invest in facilities and increase awareness through programs and public service announcements. Growing incomes, better access to facilities, and health awareness are driving growth of the large and evolving health care industry in India.
Health care industry
The health care industry in India is large and growing rapidly, expected to reach $158 billion by 2017. It makes up over 10% of GDP in developed countries. The industry is divided into hospitals, medicines/pharmacy, and medical supplies. Private sector participation has increased and now accounts for 66-81% of health care delivery. The government is also taking initiatives to invest in facilities and increase awareness through programs and public service announcements. Growing incomes, better access to facilities, and health awareness are driving growth of the large and evolving health care industry in India.
Pharmaceutical Industry Analysis
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Analysis of booming pharmaceutical sector in india
This document provides an overview of the history and growth of the Indian pharmaceutical industry. It discusses how India's growing middle class and economy have increased healthcare spending and demand for drugs. It also summarizes how disease profiles are shifting towards more chronic conditions like diabetes. Government policies aim to improve healthcare access and spending. The pharmaceutical market and exports have grown significantly in recent decades and India has become a major supplier of generic drugs globally.
Economic and sectoral impact of covid pandemic
Presentation studies the Impact of COVID on Different Sectors of Indian Stock Market. Article observes significant changes in Indian Industrial Sectors in the wake of COVID 19 Pandemic.
WellPoint 2004 summary annual report
WellPoint is working to address challenges in the US healthcare system related to affordability, access, quality care, and improved health. Regarding affordability, WellPoint is achieving administrative cost savings, helping contain healthcare costs, and providing consumers with information to help manage their own costs. For access, WellPoint is creating more affordable coverage options, finding ways to provide coverage to low-income Americans, and overcoming barriers like language and lack of local resources. Regarding quality care, WellPoint is collaborating with healthcare providers to improve clinical performance and establish evidence-based best practices. WellPoint also offers health improvement programs to help members manage chronic conditions and contribute to better health outcomes.
The future of pharma marketing
فرهاد زرگری , The Future of Pharma Marketing, Dramatic Changes, Burden of Chronic Disease, Policy-makers and Payers, Performance, Vision, Healthcare, Pharmerging, Markets, Regulatory, Prevention, Treatment, chronic diseases, diabetes, longevity, retirement age, volume sales, protocols, electronic medical records, primary-care, home delivery, multinational, innovative, aggressive marketing, detailing, promotion, Direct-to-consumer, pharmaceutical, Effectiveness, e-prescribing, self-medication, United Healthcare, Flexible Pricing,
Strategic Management presentation for a Pharmaceutical Industry
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
This document provides a summary of news and regulatory information related to the pharmaceutical industry. Key points include:
- The FDA released its strategic priorities document and is seeking public comments on how to ensure drug safety throughout a product's lifecycle.
- Novartis' Japan unit and a former employee were charged for allegedly manipulating data related to their blood pressure drug Diovan.
- The TGA published an updated summary of fees and is working to implement eCTD submissions for drug applications.
- The FDA filed a complaint seeking to permanently enjoin a California company from distributing vaginal drug products without approval.
- Industry groups in India are concerned about dependence on China for drug APIs and are calling for policies to promote
Nl healthcare oct 10 - oct 16, 2015
The Union Government will open at least 3,000 Jan Aushadhi stores by FY2017 to supply quality generic medicines across India, with 300 stores to open by FY2016. Boehringer Ingelheim and Lupin entered an agreement for Lupin to co-promote Boehringer's diabetes drug Linagliptin in India. Suven Life Sciences secured several patents for its neuro-degenerative drug across major markets such as China, South Korea, Europe, Australia and the US.
EVA pharma document
This document provides an overview of Eva Pharmaceuticals and its supply chain. It discusses how Eva Pharmaceuticals was established in 1997 as one of Egypt's leading pharmaceutical companies. It also outlines some of Eva Pharmaceuticals' key logistical activities, including quality control processes. The document summarizes the pharmaceutical industry in Egypt and how government regulations have affected it. It provides details on Eva Pharmaceuticals' target customers and corporate social responsibility initiatives through the Armanious Foundation.
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
7 Drivers: Pharmaceutical Television Advertising - John G. BareskyBare Sky Marketing Healthcare Content Writing Services
Learn about the 7 drivers of pharmaceutical television advertising. Television advertising for prescription drugs is a controversial practice but is an important component of the marketing strategy for many pharmaceutical manufacturers plus other healthcare product manufacturers. The FDA’s Center for Drug Evaluation and Research (CDER) and its Office of Prescription Drug Promotion(OPDG) closely monitor what pharmaceutical companies display and communicate within their television, print, radio or digital ads.
Get the complete insights through this article from Bare Sky Marketing Healthcare Content Writing ServicesPrescription Medicines Costs in Context July 2021
This document summarizes information from a report about prescription drug costs and spending in the United States. It notes that 53 new medicines were approved by the FDA in 2020 and discusses trends in drug spending growth rates remaining in line with overall health care spending increases. However, it also outlines challenges patients face in affording medications due to high deductibles, coinsurance, and other out-of-pocket costs not reduced by negotiated rebates and discounts. The report examines spending and policy issues across the entire U.S. health care system that contribute to the complex drug pricing landscape.
Hidden Relationships between Healthcare & Pharmaceutical Industry
Physician exposure to drug company promotions can cause their patients physical and financial suffering and provides no benefits to their prescribing practices.
Orphan Drug Report
The document summarizes key findings from EvaluatePharma's 2014 Orphan Drug Report. It finds that worldwide orphan drug sales are forecast to reach $176 billion by 2020, almost double the growth of the overall prescription drug market. Orphan drugs are expected to account for 19.1% of worldwide prescription sales by 2020. The report also notes that Soliris, used to treat rare blood disorders, generates the highest revenue per patient of any orphan drug in the US.
Market analysis report for medicines segment of healthcare industry
Brief report on medicines segment, trend in health care sector, opportunity for private player and scope.
Pharmaceutical Supply Chain Dynamics and Intelligence
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
Similar to Antibiotics to insulin (20)
Prices of essential drugs to be cut by 3% from april
Prices of essential drugs to be cut by 3% from april
Evolution of the healthcare industry in India and the potential impact of the...
Evolution of the healthcare industry in India and the potential impact of the...
Analysis of booming pharmaceutical sector in india
Analysis of booming pharmaceutical sector in india
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
Hidden Relationships between Healthcare & Pharmaceutical Industry
Hidden Relationships between Healthcare & Pharmaceutical Industry
Market analysis report for medicines segment of healthcare industry
Market analysis report for medicines segment of healthcare industry
Pharmaceutical Supply Chain Dynamics and Intelligence
Pharmaceutical Supply Chain Dynamics and Intelligence
More from Other Mother
`Selfie elbow' becoming new med condition
Doctors have warned of a new medical condition called "selfie elbow" caused by overuse from taking too many selfies. Like tennis elbow or golfer's elbow, repetitive selfie-taking can cause pain in the elbow due to inflammation from overuse. Taking too many selfies puts stress on the muscle where it attaches to the bone. The condition is treated with anti-inflammatory medication, ice, and stretching. An increasing number of teens are experiencing overuse injuries from excessive technology and social media use like gaming, Snapchat, texting, and taking selfies.
In us, one in nine men at risk of heart attack
One in nine men and one in 30 women in the US are at risk of sudden cardiac death before age 70, according to a new study. Sudden cardiac death claims around 450,000 American lives each year, often in people with no prior heart disease symptoms. Researchers examined over 5,200 men and women aged 28-62 without heart disease and found that lifetime risks were 10.9% for men and 2.8% for women based on factors like blood pressure, cholesterol, smoking, and diabetes.
Sun safety strategies for resort employees
This document provides information and strategies for sun safety among resort employees. It discusses distributing sun safety education materials to guests and providing training to employees. The training is based on a decade of sun safety programs for outdoor workers and recreators. It aims to help prevent skin cancer through promoting sun protection practices.
Transport operations
The document discusses various topics related to ambulance transport operations and safe driving practices. It covers emergency vehicle design standards, checking ambulances, en route procedures, patient transfer, defensive driving techniques, and maintaining safety while operating emergency vehicles under both normal and emergency response conditions. The overall focus is on ensuring safe and effective patient care and transport through proper vehicle operation and emergency protocols.
Aiims faculty wants hirings on hold
The Faculty Association of AIIMS has written to the institute director requesting that new recruitment of 118 assistant professors be put on hold. The association argues that there is not enough office space and residential facilities to accommodate more new hires, as 14 doctors have resigned in the last two years due to lack of work space and logistical issues. However, AIIMS administration claims that new hires are needed to address the increased patient load and allow faculty more time for research. The administration is working with the health ministry to build new facilities that will provide more office and residential spaces.
Forced to leave us, jobless researcher drags centre to hc
An Indian doctor was forced to return to India from his job in a US university less than three years after beginning work there. This was because the Indian government refused to issue him a no-obligation to return to India (NORI) certificate following a change in guidelines. He has now challenged this decision in the Bombay high court. If the NORI certificate had been issued, he could have continued his research position in the US. He is now unemployed in India as he cannot do the same specialized research elsewhere.
A project to marijuana abuse
This document discusses marijuana abuse and is presented by an organization that provides nursing and attendant staff. It covers topics such as what marijuana is, how it is used, why people use drugs, the short and long term effects of marijuana use, signs of addiction, myths and facts about marijuana, and treatment for addiction. It aims to educate about the harms of marijuana use and support recovery from addiction.
How pizza shops, steakhouses harm environment
Pizza shops and steakhouses that use charcoal or wood burning stoves produce significant emissions and damage the environment of major cities, according to a new study in Sao Paulo, Brazil. The study found emissions from thousands of pizza shops and domestic waste burning contribute to air pollution in Sao Paulo despite its green vehicle policy. A scientist estimates over 300,000 tons of wood is burned annually by pizzerias and steakhouses in Sao Paulo, negating the positive environmental effects of its biofuel policy for vehicles.
Now, `guided chemo missiles' that target only cancer cells
Scientists have developed proteins that can target and deliver chemotherapy drugs directly to cancer cells, avoiding healthy cells. These "guided missile" proteins bind to tumors and transport chemotherapy, potentially allowing higher doses that fully infiltrate hard-to-reach tumors without subjecting the whole body to toxic side effects. The proteins may also be able to cross the blood-brain barrier to treat brain cancers. This approach builds on antibody-based therapies by using engineered proteins rather than antibodies to selectively guide anti-cancer drugs.
`Not equal, some disabled need spl care'
Anant Vora, a 15-year-old student with 90% muscular dystrophy disability, cleared his CBSE Class X exams with an 8.4 CGPA despite difficulties due to not receiving specialized care for his condition. While CBSE provides writers and extra time for disabled students, his father argues each disability needs individual consideration and assistance. An advocacy group agrees comprehensive policies are needed to address diverse needs of students with varying disabilities. Anant's parents support his education despite challenges as his condition makes even sitting a problem.
Cloud over colon cancer blood test
The article discusses a new blood-based screening test for colon cancer that was recently approved by the FDA. However, experts have raised concerns about the test because it has not been shown to improve mortality rates compared to other screening methods. The test may be more effective at detecting advanced cancers rather than improving outcomes. While the test could increase screening rates by addressing challenges with current methods, doctors need more evidence that it actually reduces colon cancer deaths before widely incorporating it into practice.
Gm mosquitoes to fight malaria
Bill Gates believes that genetically modified mosquitoes could help reduce malaria deaths within the next 5 years. Researchers are developing a "gene drive" technique to alter mosquitoes so they pass on malaria resistance to nearly all offspring. This could quickly alter entire mosquito populations. While the technology may help reduce malaria, some researchers have raised concerns about potential unintended consequences if the GM mosquitoes crossbreed with other species or develop unexpected mutations. Gates remains optimistic this approach can be made safe with further testing and regulation.
Sea of trash
Marine litter has become a severe problem according to a report. Over the past three decades, more than 11.5 million people in 153 countries collected over 200 million pieces of trash from beaches and oceans through cleanup efforts. Last year alone, one organization collected over 13 million pieces of trash. The document promotes an organization that aims to improve healthcare in India by providing nurses and attendants. It provides contact information and states a mission to make quality healthcare accessible worldwide.
India faces diabetes explosion
India is facing a diabetes epidemic as the number of diabetics is projected to increase to over 100 million in the next 15 years. While India has made progress in reducing childhood stunting, there are growing concerns about the rise in overweight and obese populations that are prone to diabetes. Public health policies need to be strengthened to address both undernutrition and overnutrition issues like diabetes.
Heart disease, cholesterol not linked
An international team of scientists reviewed 19 previous studies involving 68,000 elderly people and found no link between high LDL cholesterol levels and heart disease in those over 60. The study suggests that 92% of elderly people with high cholesterol lived as long or longer than those with low cholesterol, and statin prescriptions may be unnecessary for the elderly. However, some academics have criticized the research methods and questioned the bias of the authors.
1st `tampon disease' vaccine developed
Scientists have developed the world's first vaccine for Toxic Shock Syndrome (TSS), a severe illness caused by bacterial toxins that often affects young women using tampons during their periods. The vaccine was successfully tested in an initial Phase I human trial. TSS, also known as "tampon disease," causes symptoms of sepsis and was first linked to the use of highly absorbent "super tampons" in the 1980s, leading regulators to limit tampon absorbency. The new vaccine could provide protection against the bacterial toxins that cause this potentially life-threatening condition.
Stress and coping
The document discusses stress, its definitions, causes, and physiological effects. It defines stress as the body's response to any demand, and notes that stress can be positive (eustress) or negative (distress) depending on its intensity and duration. Prolonged stress activates the sympathetic nervous system and HPA axis, releasing hormones like cortisol that prepare the body for "fight or flight." However, if stress is chronic it can lead to health problems through the general adaptation syndrome. The cognitive-transactional model holds that stress depends more on one's appraisal and coping abilities than external factors alone. Problem-focused and emotion-focused coping strategies aim to manage stress' psychological and physiological impacts. Maintaining a sense
Evolution of contraception
The document discusses the evolution of contraceptive methods from ancient times to modern progestin-based contraceptives. It traces the development from potentially dangerous ancient methods like using crocodile dung or lead and arsenic potions, to the first modern contraceptives developed in the 1930s using ovarian hormone extracts. It then summarizes many current progestin-based contraceptive options including oral contraceptives, implants, IUDs, injections, and barriers methods. The document provides details on the mechanisms of action, effectiveness, side effects, and appropriate use for these various contraceptive methods.
Toxins in sippy cups a threat to babies
A study found bisphenol A (BPA), a known endocrine disruptor, in 77% of sippy cup samples tested in Delhi. BPA was detected in concentrations as high as 14.9 ppm and can interfere with hormone functions and impact growth in babies. While BPA is now prohibited in baby bottles, there are no regulations on its use in sippy cups.
70% of indians eat non veg, but veg diet getting popular
While 70% of Indians still eat non-vegetarian diets, that number is expected to decline as a vegetarian diet becomes more popular due to increasing health awareness. Rising rates of lifestyle diseases are influencing people to change their diets. Additionally, international studies have shown vegetarians to be healthier than meat-eaters. However, consumption and purchase of chicken and fish is still growing rapidly in India.
More from Other Mother (20)
Forced to leave us, jobless researcher drags centre to hc
Forced to leave us, jobless researcher drags centre to hc
Now, `guided chemo missiles' that target only cancer cells
Now, `guided chemo missiles' that target only cancer cells
70% of indians eat non veg, but veg diet getting popular
70% of indians eat non veg, but veg diet getting popular
Recently uploaded
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
une 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Pharmacology of 5-hydroxytryptamine and Antagonist
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Foundation of Yoga, YCB Level-3, Unit-1
Unit -1 of Yoga certification board, level 3, all topics covered. An exam conducted by ministry of Ayush for yoga enthusiastic students.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
Sensation is the neurological process by which we become aware of surrounding environment.
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montrealArtificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
Breast cancer: Post menopausal endocrine therapy
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Skin Diseases That Happen During Summer.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
How to choose the best dermatologists in Indore.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Patellar Instability: Diagnosis Management
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
Recently uploaded (20)
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Antibiotics to insulin
- 1. Antibiotics to insulin: Key drugs to cost 4% more Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 2. Contd.. Essential medicines including insulin, hepatitis injection, antidiabetes drugs, antibiotics and some of the cancer medicines have become costlier by 3.8% starting April 1.The hike could be significant as some of these drugs are already expensive. The government has allowed pharmaceutical firms to raise prices of 509 formulation packs, in line with the annual increase in the Wholesale Price Index (WPI).The latest hike also applies on condoms, which are part of the list of essential medicines -prices of which are capped by the government. The list of 509 medicines include Alpha Interferon injection used to treat hepatitis B and C as well as certain types of cancer, carboplatin injection also used for cancer treatment, fluconazole capsules indicated for fungal infections, among others. Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 3. Contd.. This is the first time the government has allowed a hike in prices of medicines ever since BJP took office at the Centre. In fact, the hike has its roots in the drug pricing policy which mandates an annual revision of ceiling prices of regulated pharmaceutical products based on the WPI. The government direct ly caps prices of a total of 348 essential medicines based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1%.Besides, the government also regulates prices of all other medicines and companies are allowed to hike prices of such drugs only up to 10% in a year. Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 4. Contd.. Immunization drive begins in 28 states One of the world's largest child immunization programmes rolled out on Tuesday across 201 districts and 28 states of the country. Depicting seven colours of the rainbow, `Mission Indradhanush' aims to cover by 2020 all such infants who are either unvaccinated or are partially vaccinated against-diphtheria, whooping cough, tetanus, polio, tuberculosis, measles and hepatitis B. Sushmi Dey 2 pharma cos can get more fgn funds In a move that would boost foreign investment, the Union Cabinet on Tuesday approved proposals by two major pharmaceutical firms -Aurobindo Pharma and Glenmark -allowing them to raise funds through increase in foreign investment ceiling. With the cl earance, Aurobindo Pharma will get a fund injection of ab out Rs 2,165 crore while Glen mark will get investments worth Rs 2,022 crore. Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 5. This platform has been started by Parveen Kumar Chadha with the vision that nobody should suffer the way he has suffered because of lack and improper healthcare facilities in India. We need lots of funds manpower etc. to make this vision a reality please contact us. Join us as a member for a noble cause. Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 6. Our views have increased the mark of the 99,000 Thank you viewers Looking forward for franchise, collaboration, partners. Brought to you by The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:-
- 7. 011-25464531, 011-41425180, 011-66217387 +91-9818308353,+91-9818569476 othermotherindia@gmail.com www.other-mother.in https://www.facebook.com/pages/Other-Mother-Nursing-Crusade/224235031114989?ref=hl http://www.linkedin.com/profile/view?id=326103341&trk=nav_responsive_tab_profile https://twitter.com/othermotherindi https://cparveen.wix.com/other-mother A WORLDWIDE MISSITION Contact Us:- JOIN US www.parveenchadha.com The Nurses and attendants staff we provide for your healthy recovery for bookings Contact Us:- We are also available on Justdial New Delhi.